Clinical trials have confirmed that FUS enables safe and transient BBB/BTB opening in localized brain regions, significantly increasing the concentrations of systemically administered drugs, such as trastuzumab, carboplatin, TMZ, liposomal DOX, and albumin-bound PTX, within brain tumors [483]. The gene discussed is ALB; the disease is brain neoplasm.